Shin Sang-Chul, Cho Cheong-Weon
College of Pharmacy, Chonnam National University, Gwangju 500-757, Korea.
Arch Pharm Res. 2006 Oct;29(10):928-33. doi: 10.1007/BF02973916.
Percutaneous delivery of NSAIDs has advantages of avoiding hepatic first pass effect and delivering the drug for extended period of time at a sustained, concentrated level at the inflammation site that mainly acts at the joint and the related regions. To develop the new topical formulations of pranoprofen that have suitable bioadhesion, the gel was formulated using hydroxypropyl methylcellulose (HPMC) and poloxamer 407. The effects of temperature on drug release was performed at 32 degrees C, 37 degrees C and 42 degrees C according to drug concentration of 0.04%, 0.08%, 0.12%, 0.16%, and 0.2% (w/w) using synthetic cellulose membrane at 37+/-0.5 degrees C. The increase of temperature showed the increased drug release. The activation energy (Ea), which were calculated from the slope of lop P versus 1000/T plots was 11.22 kcal/ mol for 0.04%, 10.79 kcal/mol for 0.08%, 10.41 kcal/mol for 0.12% and 8.88 kcal/mol for 0.16% loading dose from the pranoprofen gel. To increase the drug permeation, some kinds of penetration enhancers such as the ethylene glycols, the propylene glycols, the glycerides, the non-ionic surfactants and the fatty acids were incorporated in the gel formulation. Among the various enhancers used, propylene glycol mono laurate showed the highest enhancing effects with the enhancement factor of 2.74. The results of this study suggest that development of topical gel formulation of pranoprofen containing an enhancer is feasible.
非甾体抗炎药的经皮给药具有避免肝脏首过效应的优点,并且能够在炎症部位以持续、浓缩的水平长时间给药,主要作用于关节及相关区域。为开发具有合适生物黏附性的新的普拉洛芬局部用制剂,使用羟丙基甲基纤维素(HPMC)和泊洛沙姆407制备了凝胶。根据药物浓度为0.04%、0.08%、0.12%、0.16%和0.2%(w/w),在37±0.5℃下使用合成纤维素膜,于32℃、37℃和42℃进行温度对药物释放的影响实验。温度升高显示药物释放增加。从log P对1000/T图的斜率计算得到的活化能(Ea),对于普拉洛芬凝胶中0.04%的载药量为11.22千卡/摩尔,0.08%为10.79千卡/摩尔,0.12%为10.41千卡/摩尔,0.16%为8.88千卡/摩尔。为增加药物渗透,在凝胶制剂中加入了一些渗透促进剂,如乙二醇、丙二醇、甘油酯、非离子表面活性剂和脂肪酸。在所使用的各种促进剂中,月桂酸单丙二醇酯显示出最高的促进效果,增强因子为2.74。本研究结果表明,开发含有促进剂的普拉洛芬局部用凝胶制剂是可行的。